What can we help you find?

Leading the way in transplantation

Filter results for:


Hansa Biopharma is a pioneering biopharmaceutical company and our mission is to develop innovative, lifesaving and life-changing treatments for patients with rare immunological conditions. Hansa has developed a first-in-class Immunoglobulin-G (IgG) antibody cleaving enzyme therapy, which can enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program exploring a broad range of conditions. Our pipeline is focussed on advancing the Company’s proprietary enzyme technology to develop the next generation of IgG-cleaving enzymes to enable repeat dosing in relapsing

Back Visit the website